Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.
about
Repurposing metformin: an old drug with new tricks in its binding pocketsRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitusInfluence of Plantago ovata husk (dietary fiber) on the bioavailability and other pharmacokinetic parameters of metformin in diabetic rabbitsManagement of metformin-associated lactic acidosis by continuous renal replacement therapyOral medications for treating diabetes mellitus in dogs and cats.Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis.Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium.Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trialEffect of gastric bypass surgery on the absorption and bioavailability of metformin.Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.Therapeutic Concentrations of Metformin: A Systematic Review.Population PK/PD analysis of metformin using the signal transduction model.The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.Polymorphism in human organic cation transporters and metformin action.A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate.Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1.Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters.Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1.Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice.Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module.Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.Disposition of metformin: variability due to polymorphisms of organic cation transporters.Transitioning from inpatient to outpatient therapy in patients with in-hospital hyperglycemia.Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs.A prospective analysis of co-processed non-ionic surfactants in enhancing permeability of a model hydrophilic drug.Metformin-related lactic acidosis: is it a myth or an underestimated reality?Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome.Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase.Pharmacokinetics of metformin gastric-retentive tablets in healthy volunteers.Bioequivalence evaluation of two brands of metformin 500 mg tablets (Dialon & Glucophage)--in healthy human volunteers.Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart.Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus.Inhibition of the multidrug and toxin extrusion (MATE) transporter by pyrimethamine increases the plasma concentration of metformin but does not increase antihyperglycaemic activity in humans.Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.ATP-sensitive K(+) Channels in the Regulation of Feeding Behavior: A Hypothesis.
P2860
Q22250976-F5131CF7-F472-4145-A259-D33EE4D4A580Q24235718-654251D6-0DA9-4825-8F94-D95D88EEF7DEQ24240522-ED36187F-72ED-42AC-A7EE-0D987D3F7F06Q33776193-C9E13039-0BB7-459A-B884-21C3E810D13AQ33996972-7A53EC42-6ED9-48EB-A646-EAB1FDB7AB27Q34098405-B1A9C314-F9BD-42B4-8A3D-5279FA653C3FQ34292544-368FBD0D-76DB-4A20-8588-EE461C74AE0BQ34421386-FA2000C4-CB5D-4632-9F50-1DD99816A565Q34505650-F585298D-E8B9-4855-B436-8E7A0B89943AQ34611894-72763DB2-EEF5-4CAC-B6E6-5CCB6075E1E0Q35043256-161DB16D-DB7D-49B0-A566-87D0C38A9BBBQ35164428-04B4A474-56FC-4876-93FF-BF015D4266FBQ35761723-FF321FAD-6CAA-4738-963C-77096C08F66BQ36390254-5242F60B-0F65-4B16-A0BA-B590BA4CA316Q36899802-57EC7FD2-FE05-4B91-8523-6E39F620D2FBQ36924379-F850BE20-AB30-493D-928B-12A7487A19A3Q37126649-FDB4B8D4-7A3F-4D63-B222-43F7EB40B599Q37170305-497C8DB6-C20F-4947-A360-492C77DE6229Q37171418-A8A761C3-DC42-4EAF-9F3E-EAEFC107AF1AQ37369333-9DF654A4-C48F-415F-AEC5-F34D1949981CQ37522894-FF61380E-CEBE-4B35-8191-0B911CB7C005Q37656702-01148403-E19E-4E93-9ECE-42F2D2B22F7FQ37688736-D28A1F71-0CF7-4E50-A055-06D0198A9C0DQ37710586-89B061D2-D1F6-4686-976D-CC8AC9823C46Q37848844-23A28841-1660-464F-BB5A-C8687137ED58Q37953155-56BCFE38-F040-4538-9C02-CECBB9BB04EDQ38016232-0F9AB85F-0ECB-4019-87F0-F02D20699B37Q38554851-B2BE69B8-3E01-4FD5-A71E-24DE66AEC284Q38968059-4E5EDE5C-A1E3-4A45-8619-46B6EA6E0340Q39754625-E279DAF9-13C5-4283-B2D0-ED70C946297CQ43560157-F18E0DE5-45C1-45E8-86D4-299BEF87EE74Q43637279-A1835E2C-A543-4D5A-A074-7D1F67BE11BEQ44159894-68CAC91E-FE39-4C41-B519-3F3A8B7B5CC1Q44242299-87191EFB-5F91-40C3-A8D8-B2EB112FA75FQ46240789-53A8FA98-2184-4F2A-8B8C-45421F149C7FQ46677274-FDB056A6-01BE-4E76-8400-BE70FD549F7CQ53195434-CDF09A87-2A3D-44B4-A9DB-7773EB95B99BQ53594745-C504CF9E-C507-4039-BF4B-7B0F35F00817Q54097440-B8B7D82D-BE61-4ED0-9206-A559A010B55CQ54173930-7CC23E2A-B107-4353-B34D-9AF31310E1A7
P2860
Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus.
description
1996 nî lūn-bûn
@nan
1996 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@ast
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@en
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@nl
type
label
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@ast
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@en
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@ast
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@en
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@nl
P2093
P2860
P1476
Pharmacokinetics and pharmacod ...... n-dependent diabetes mellitus.
@en
P2093
Goodman AM
O'Conner M
P2860
P304
P356
10.1177/009127009603601105
P577
1996-11-01T00:00:00Z